| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00314984 |
| P953 | full work available at URL | http://link.springer.com/article/10.1007/BF00314984/fulltext.html |
| http://link.springer.com/content/pdf/10.1007/BF00314984 | ||
| http://link.springer.com/content/pdf/10.1007/BF00314984.pdf | ||
| P698 | PubMed publication ID | 1667755 |
| P2093 | author name string | C. Zanussi | |
| F. Polvani | |||
| T. Nencioni | |||
| S. Ortolani | |||
| M. Cortellaro | |||
| C. Boschetti | |||
| B. Francucci | |||
| F. Buzzi | |||
| M. P. Caraceni | |||
| P. Abelli | |||
| P2860 | cites work | Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens | Q28320364 |
| Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations | Q28367117 | ||
| Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females | Q36595158 | ||
| Endometrial responses to transdermal estradiol in postmenopausal women | Q38520588 | ||
| Menopausal Estrogens and Breast Cancer | Q39997555 | ||
| Noncontraceptive estrogens and nonfatal myocardial infarction | Q40136290 | ||
| Plasma fibrinogen--a major coronary risk factor | Q41879314 | ||
| Cardiovascular risk and use of estrogens or estrogen-progestagen combinations. Stanford three-community study | Q44361085 | ||
| The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss | Q44573939 | ||
| Parathyroid hormone secretion: effect of estradiol and progesterone | Q45258981 | ||
| Low Fibrinolytic Activity of Veins During Treatment with Ethinylo Estradiol | Q45264506 | ||
| Association of Exogenous Estrogen and Endometrial Carcinoma | Q46021645 | ||
| Estrogen replacement therapy. | Q47411492 | ||
| Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women | Q49037543 | ||
| Replacement estrogens and endometrial cancer. | Q50538063 | ||
| Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. | Q51633467 | ||
| Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 | ||
| Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: Comparison with conventional oral estrogens used for hormone replacement | Q55879652 | ||
| Effects of Estradiol and Progesterone on Parathyroid Hormone Secretion From Human Parathyroid Tissue* | Q68291610 | ||
| Evidence of estrogen receptors in normal human osteoblast-like cells | Q68424951 | ||
| Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women | Q68926605 | ||
| Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study | Q69886150 | ||
| Treatment of hot flashes with transdermal estradiol administration | Q69960628 | ||
| Biologic effects of transdermal estradiol | Q70140885 | ||
| Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration | Q70275929 | ||
| Estrogen replacement therapy by transdermal estradiol administration | Q70436182 | ||
| The role of sex hormones and synthetic steroids in prevention of post-menopausal osteoporosis | Q70449231 | ||
| At III content and antithrombin in activity in oestrogen-progestogen and progestogen-only treated women | Q71317492 | ||
| Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens | Q72458904 | ||
| Effect of Estrogen on Calcium Absorption and Serum Vitamin D Metabolites in Postmenopausal Osteoporosis* | Q72872506 | ||
| Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women | Q72938797 | ||
| Contemporary therapy of the menopausal syndrome | Q78810038 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 555-559 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment | |
| P478 | volume | 41 |
| Q54002942 | Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System. |
| Q43814222 | Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state |
| Q62607064 | EFFECTS OF ESTROGEN REPLACEMENT THERAPY ON THROMBIN GENERATION |
| Q48713124 | Effects of norethisterone acetate addition to estradiol in long term HRT. |
| Q39432071 | Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints |
| Q33560669 | Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease |
| Q50075574 | Metabolic syndrome in menopause and associated factors: a meta-analysis |
| Q41295558 | New developments in topical estrogen therapy |
| Q36316846 | Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery |
| Q73229439 | Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women |
| Q47933421 | The relationship between oestrogen and executive functioning in ALS females with emerging Frontotemporal Lobar Degeneration (FTLD) supports a neuroendocrine model of FTLD attenuation |
| Q35664612 | Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis |
| Q40760251 | Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women |
Search more.